• Ovixan® (Galencia, Malmoe, Sweden) is a novel, oil in water formulation of mometasone furoate for inflammatory skin disorders, which is less greasy, sticky, and smelly than the commonly used mometasone formulation, Elocon® (Merck [Schering-Plough], Whitehouse Station, New Jersey. USA), which is a water in oil formulation.

• The skin blanching effect of Ovixan in a vasoconstrictor assay in 30 volunteers was the same as the effect of the leading mometasone formulation.

• The clinical efficacy of Ovixan was compared to the leading mometasone formulation and their vehicles in a multicenter, randomized, double-blind clinical study in which 61 patients with mild-to-moderate plaque psoriasis were included.

• After treatment for 6 weeks, there was no significant difference in Total Severity Sign score reduction from baseline by Ovixan and the leading formulation.

• Ovixan is an effective formulation of mometasone furoate with different cosmetic properties than the leading formulation, and constitutes an effective addition to the armamentarium for treatment of psoriasis and other inflammatory skin disorders.

This summary slide represents the opinions of the authors, and not necessarily the opinions of the publisher or editorial board. Sponsorship for this study and summary slide was funded by Galenica AB, 205 12 Malmö, Sweden.